HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $8 price target.